AZN•benzinga•
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
Summary
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 6, 2025 by benzinga